Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro

Roche joins others in dropping myostatin inhibitor for DMD

Allergan gets FDA okay for paediatric Botox use

NS Pharma steals a march on Sarepta with DMD drug